Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Polypid Ltd.

Headquarters: Petah Tikva, Israel
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Dikla Czaczkes Akselbrad, MBA, CPA
Number Of Employees: 61
Enterprise Value: $11,783,186
PE Ratio: -0.59
Exchange/Ticker 1: NASDAQ:PYPD
Exchange/Ticker 2: N/A
Latest Market Cap: $29,961,200

BioCentury | Jan 3, 2022
Management Tracks

Robertson becomes Opthea’s first CCO

Plus: 4D Pharma, NeuShen, Mind, PolyPid and Biosion
BioCentury | Mar 17, 2021
Finance

European IPOs look to U.S. markets: Data Byte

2020’s top European biotech IPOs listed on NASDAQ, NYSE
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

Fusion, PolyPid join the gene therapy company on NASDAQ, Hyloris prices IPO on Euronext
BioCentury | Feb 29, 2016
Financial News

PolyPid completes venture financing

BioCentury | Feb 25, 2016
Financial News

PolyPid's D round brings in $22M

BioCentury | Mar 30, 2015
Financial News

PolyPid withdraws IPO

Items per page:
1 - 10 of 22